Integrating Tobacco Treatment into Cancer Care

描述（由申请人提供）：为了响应健康传播和实施研究PAR 10-38，我们建议研究两种基于证据的烟草治疗与现实世界癌症护理环境的整合。癌症诊断后戒烟可以通过减少手术、放疗或化疗并发症以及降低第二原发肿瘤的风险来提高患者的生活质量和改善治疗效果。在诊断时，大约10-30%的癌症患者是吸烟者，其中许多人具有较高的社会经济、生物和心理脆弱性。美国卫生与公众服务部公共卫生服务处有基于证据的烟草治疗指南，但这些指南尚未纳入癌症治疗。美国临床肿瘤学会（American Society of Clinical Oncology）的一项核心质量指标是在所有吸烟者第二次癌症就诊时对其进行识别、建议和咨询，但目前还没有达到这些质量标准。为了解决这一治疗差距，我们建议进行第一个比较有效性试验，以评估两种循证烟草治疗在新诊断癌症患者中的有效性。我们的建议是基于Park博士在一项非随机对照试点研究（5R03CA130722-02）中的发现，该研究显示了在马萨诸塞州总医院（MGH）为新诊断的肺癌患者提供循证强化治疗（IT）的可行性和有效性。我们建议在MGH和纪念斯隆-凯特琳癌症中心（MSK）招募295名新诊断为肺癌、结肠癌、乳腺癌或前列腺癌（四种最常见的癌症）的吸烟者，并比较提供强化治疗（IT； 10个动机咨询会议加12周FDA批准的戒烟药物）与简短治疗(BT；MSK目前提供的治疗是4次动机咨询会议加上药物建议)。目的1将比较两种烟草处理在6个月时促进生化证实的烟草戒烟的有效性。目的2将评估通过治疗促进戒断的机制，促进戒断的亚群，以及促进戒断的治疗方面。目标3将探讨有多少吸烟者参加并坚持烟草治疗。这个建议的独特之处在于它的理论结合了慢性疾病（自我调节）

DESCRIPTION (provided by applicant): In response to the Dissemination and Implementation Research in Health PAR 10-38, we propose to examine the integration of two evidence-based tobacco treatments into real-world cancer care settings. Quitting smoking after cancer diagnosis may increase patients' quality of life and improve treatment outcomes through decreases in complications from surgery, radiation or chemotherapy, and decreases in risk of second primary tumors. At diagnosis, approximately 10-30% of cancer patients are smokers, and many have elevated socioeconomic, biologic, and psychosocial vulnerabilities. The U.S. Department of Health and Human Services Public Health Service has evidence-based tobacco treatment guidelines, but these have not been integrated into cancer care. An American Society of Clinical Oncology core quality indicator is identification, advice, and counseling of all smokers by their second cancer visit, but these quality standards are not being met. To address this treatment gap, we propose to conduct the first comparative effectiveness trial to assess the effectiveness of two evidence-based tobacco treatments among newly diagnosed cancer patients. Our proposal is guided by Dr. Park's findings from a nonrandomized controlled pilot study (5R03CA130722-02) which showed promising feasibility and efficacy for delivering an evidence-based Intensive Treatment (IT) to newly diagnosed lung cancer patients at Massachusetts General Hospital (MGH). We propose to enroll 295 current smokers newly diagnosed with lung, colon, breast, or prostate cancer (the four most prevalent cancers) at MGH and Memorial Sloan Kettering Cancer Center (MSK) and compare the differential effectiveness of delivering an Intensive Treatment (IT; 10 motivational counseling sessions plus 12 weeks of FDA approved smoking cessation medication) versus a Brief Treatment (BT; the current treatment provided at MSK, which is 4 motivational counseling sessions plus medication advice). Aim 1 will compare the effectiveness of the two tobacco treatments in promoting biochemically confirmed tobacco abstinence at 6 months. Aim 2 will assess mechanisms through which treatment promotes abstinence, subpopulations in which abstinence is promoted, and aspects of treatment that promote abstinence. Aim 3 will explore how many smokers enroll in, and adhere to, tobacco treatment. This proposal is unique in its 1) theory [(combining a chronic illness (Self-Regulation) and behavior change (Health Belief) model)], 2) integrated tobacco treatments (targeted to patients undergoing cancer treatment), and 3) collaborative care model (sustainable and facilitated through state-of- the art electronic health record systems). Study findings will addres previously unanswered questions about provision of integrated tobacco treatment as part of comprehensive cancer care. Furthermore, it will provide information to lay the groundwork for dissemination efforts into a variety of cancer care settings.